Limits...
Effect of pretreatment with transdermal testosterone on poor ovarian responders undergoing IVF/ICSI: A meta-analysis.

Luo S, Li S, Li X, Qin L, Jin S - Exp Ther Med (2014)

Bottom Line: The meta-analysis revealed that females who received transdermal testosterone treatment prior to their IVF/ICSI cycle had a two-fold increase in live birth rate [risk ratio (RR)=2.01, 95% confidence interval (CI) 1.03-3.91], clinical pregnancy rate (RR=2.09, 95% CI 1.14-3.81) and a significantly more oocyte retrieved [mean difference (MD)=1.36, 95% CI 0.82-1.90].However, the results should be interpreted with caution due to the small sample size of the studies used and the heterogeneities.Further good quality RCTs would be needed to reach further conclusions.

View Article: PubMed Central - PubMed

Affiliation: Reproductive Medical Center, Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China.

ABSTRACT
In order to identify and describe the effectiveness of transdermal testosterone pretreatment on poor ovarian responders, MEDLINE, EMBASE, the Cochrane library and the Chinese biomedical database were searched for randomized controlled trials (RCTs). Three RCTs, which compared the outcomes of female pretreatment with transdermal testosterone prior to in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) with those of control groups, were included in the present review. The three RCTs enrolled a total of 221 randomized subjects. The meta-analysis revealed that females who received transdermal testosterone treatment prior to their IVF/ICSI cycle had a two-fold increase in live birth rate [risk ratio (RR)=2.01, 95% confidence interval (CI) 1.03-3.91], clinical pregnancy rate (RR=2.09, 95% CI 1.14-3.81) and a significantly more oocyte retrieved [mean difference (MD)=1.36, 95% CI 0.82-1.90]. The current findings provide evidence that pretreatment with transdermal testosterone may improve the clinical outcomes for poor ovarian responders undergoing IVF/ICSI. However, the results should be interpreted with caution due to the small sample size of the studies used and the heterogeneities. Further good quality RCTs would be needed to reach further conclusions.

No MeSH data available.


Meta-analysis of transdermal testosterone pretreatment groups vs. the control groups for number of oocytes retrieved in poor ovarian responders undergoing in vitro fertilization treatment. CI, confidence interval.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4061182&req=5

f4-etm-08-01-0187: Meta-analysis of transdermal testosterone pretreatment groups vs. the control groups for number of oocytes retrieved in poor ovarian responders undergoing in vitro fertilization treatment. CI, confidence interval.

Mentions: Low ovarian responders were characterized as those having ≤3 oocytes retrieved despite the use of a high gonadotropin dose in previous failed IVF/ICSI cycles. They often faced the risk of cycle cancellation due to fewer developing follicles following COH. Thus, the number of oocytes retrieved was the most direct index used to evaluate the ovarian response to gonadotropin stimulation. All three studies reported a change in the number of oocytes retrieved and meta-analysis revealed that more oocytes were retrieved from the testosterone pretreatment group than from the control group [mean difference (MD)=1.36, 95% CI 0.82–1.90; Fig. 4].


Effect of pretreatment with transdermal testosterone on poor ovarian responders undergoing IVF/ICSI: A meta-analysis.

Luo S, Li S, Li X, Qin L, Jin S - Exp Ther Med (2014)

Meta-analysis of transdermal testosterone pretreatment groups vs. the control groups for number of oocytes retrieved in poor ovarian responders undergoing in vitro fertilization treatment. CI, confidence interval.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4061182&req=5

f4-etm-08-01-0187: Meta-analysis of transdermal testosterone pretreatment groups vs. the control groups for number of oocytes retrieved in poor ovarian responders undergoing in vitro fertilization treatment. CI, confidence interval.
Mentions: Low ovarian responders were characterized as those having ≤3 oocytes retrieved despite the use of a high gonadotropin dose in previous failed IVF/ICSI cycles. They often faced the risk of cycle cancellation due to fewer developing follicles following COH. Thus, the number of oocytes retrieved was the most direct index used to evaluate the ovarian response to gonadotropin stimulation. All three studies reported a change in the number of oocytes retrieved and meta-analysis revealed that more oocytes were retrieved from the testosterone pretreatment group than from the control group [mean difference (MD)=1.36, 95% CI 0.82–1.90; Fig. 4].

Bottom Line: The meta-analysis revealed that females who received transdermal testosterone treatment prior to their IVF/ICSI cycle had a two-fold increase in live birth rate [risk ratio (RR)=2.01, 95% confidence interval (CI) 1.03-3.91], clinical pregnancy rate (RR=2.09, 95% CI 1.14-3.81) and a significantly more oocyte retrieved [mean difference (MD)=1.36, 95% CI 0.82-1.90].However, the results should be interpreted with caution due to the small sample size of the studies used and the heterogeneities.Further good quality RCTs would be needed to reach further conclusions.

View Article: PubMed Central - PubMed

Affiliation: Reproductive Medical Center, Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China.

ABSTRACT
In order to identify and describe the effectiveness of transdermal testosterone pretreatment on poor ovarian responders, MEDLINE, EMBASE, the Cochrane library and the Chinese biomedical database were searched for randomized controlled trials (RCTs). Three RCTs, which compared the outcomes of female pretreatment with transdermal testosterone prior to in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) with those of control groups, were included in the present review. The three RCTs enrolled a total of 221 randomized subjects. The meta-analysis revealed that females who received transdermal testosterone treatment prior to their IVF/ICSI cycle had a two-fold increase in live birth rate [risk ratio (RR)=2.01, 95% confidence interval (CI) 1.03-3.91], clinical pregnancy rate (RR=2.09, 95% CI 1.14-3.81) and a significantly more oocyte retrieved [mean difference (MD)=1.36, 95% CI 0.82-1.90]. The current findings provide evidence that pretreatment with transdermal testosterone may improve the clinical outcomes for poor ovarian responders undergoing IVF/ICSI. However, the results should be interpreted with caution due to the small sample size of the studies used and the heterogeneities. Further good quality RCTs would be needed to reach further conclusions.

No MeSH data available.